PURPOSE: We sought to identify prognostic factors-including positron emission tomography (PET) parameters-in patients with previously untreated squamous carcinoma of the uterine cervix and MRI- or CT-defined pelvic or para-aortic lymph node (PLN or PALN) metastasis. MATERIALS AND METHODS: Patients with untreated squamous cell cervical cancer and PLN or PALN metastasis detected by CT/MRI were enrolled. FDG-PET scans were performed for primary staging. Prognostic variables were investigated by univariate and multivariate analyses. Five-year recurrence-free and 5-year overall survivals (RFS and OS) were evaluated using the Kaplan-Meier method. RESULTS: A total of 70 patients [54 patients with International Federation of Gynecology and Obstetrics (FIGO) stage I or II, and 16 patients with stage III or IV] were eligible. Follow-up ranged from 26.1 to 71.6 months. In multivariate analysis, FIGO stage > or =III (5-year RFS, p = 0.008; 5-year OS, p = 0.008) was a significant prognostic factor for both RFS and OS. In addition, SUV(max) for PALN (dichotomized by 3.3) was significantly associated with OS (p = 0.012) and marginally with RFS (p = 0.078). The presence of SUV(max) > or = 3.3 at PALN or FIGO stage > or =III were significantly associated with both recurrence [5-year RFS; HR = 4.52, 95% confidence interval (CI) = 1.73-11.80] and death (5-year OS; HR = 6.04, 95% CI = 1.97-18.57). CONCLUSION: SUV(max) > or = 3.3 for PALN and FIGO stage > or =III were significant adverse factors in patients with primary squamous cervical carcinoma and PLN or PALN metastasis detected by CT/MRI.
PURPOSE: We sought to identify prognostic factors-including positron emission tomography (PET) parameters-in patients with previously untreated squamous carcinoma of the uterine cervix and MRI- or CT-defined pelvic or para-aortic lymph node (PLN or PALN) metastasis. MATERIALS AND METHODS: Patients with untreated squamous cell cervical cancer and PLN or PALN metastasis detected by CT/MRI were enrolled. FDG-PET scans were performed for primary staging. Prognostic variables were investigated by univariate and multivariate analyses. Five-year recurrence-free and 5-year overall survivals (RFS and OS) were evaluated using the Kaplan-Meier method. RESULTS: A total of 70 patients [54 patients with International Federation of Gynecology and Obstetrics (FIGO) stage I or II, and 16 patients with stage III or IV] were eligible. Follow-up ranged from 26.1 to 71.6 months. In multivariate analysis, FIGO stage > or =III (5-year RFS, p = 0.008; 5-year OS, p = 0.008) was a significant prognostic factor for both RFS and OS. In addition, SUV(max) for PALN (dichotomized by 3.3) was significantly associated with OS (p = 0.012) and marginally with RFS (p = 0.078). The presence of SUV(max) > or = 3.3 at PALN or FIGO stage > or =III were significantly associated with both recurrence [5-year RFS; HR = 4.52, 95% confidence interval (CI) = 1.73-11.80] and death (5-year OS; HR = 6.04, 95% CI = 1.97-18.57). CONCLUSION: SUV(max) > or = 3.3 for PALN and FIGO stage > or =III were significant adverse factors in patients with primary squamous cervical carcinoma and PLN or PALN metastasis detected by CT/MRI.
Authors: Matthias H M Schwarzbach; Ulf Hinz; Antonia Dimitrakopoulou-Strauss; Frank Willeke; Servando Cardona; Gunhild Mechtersheimer; Thomas Lehnert; Ludwig G Strauss; Christian Herfarth; Markus W Büchler Journal: Ann Surg Date: 2005-02 Impact factor: 12.969
Authors: N Sakuragi; C Satoh; N Takeda; H Hareyama; M Takeda; R Yamamoto; T Fujimoto; M Oikawa; T Fujino; S Fujimoto Journal: Cancer Date: 1999-04-01 Impact factor: 6.860
Authors: Feiyu Xue; Lilie L Lin; Farrokh Dehdashti; Tom R Miller; Barry A Siegel; Perry W Grigsby Journal: Gynecol Oncol Date: 2005-11-02 Impact factor: 5.482
Authors: J H Hong; C S Tsai; J T Chang; C C Wang; C H Lai; S P Lee; C J Tseng; T C Chang; S G Tang Journal: Int J Radiat Oncol Biol Phys Date: 1998-07-01 Impact factor: 7.038